Iliopoulos D, Malizos K N, Tsezou A
University of Thessalia, Medical School, Department of Biology, 22 Papakyriazi str. 41 222 Larisa, Greece.
Ann Rheum Dis. 2007 Dec;66(12):1616-21. doi: 10.1136/ard.2007.069377. Epub 2007 May 14.
To investigate whether epigenetic mechanisms can regulate leptin's expression and affect its downstream targets as metalloproteinases 3,9,13 in osteoarthritic chondrocytes.
DNA methylation in leptin promoter was measured by DNA bisulfite sequencing, and mRNA expression levels were measured by real-time quantitative PCR in osteoarthritic as well as in normal cartilage. Osteoarthritic articular cartilage samples were obtained from two distinct locations of the knee (n = 15); from the main defective area of maximum load (advanced osteoarthritis (OA)) and from adjacent macroscopically intact regions (minimal OA). Using small interference RNA, we tested if leptin downregulation would affect matrix metalloproteinase (MMP)-13 activity. We also evaluated the effect of the demethylating agent, 5'-Aza-2-deoxycytidine (AZA) and of the histone deacetylase inhibitor trichostatin A (TSA) on leptin expression in chondrocyte cultures. Furthermore, we performed chromatin immunoprecipitation in leptin's promoter area.
We found a correlation between leptin expression and DNA methylation and also that leptin controls MMP-13 activity in chondrocytes. Leptin's downregulation with small interference RNA inhibited MMP-13 expression dramatically. After 5-AZA application in normal chondrocytes, leptin's methylation was decreased, while its expression was upregulated, and MMP-13 was activated. Furthermore, TSA application in normal chondrocyte cultures increased leptin's expression. Also, chromatin immunoprecipitation in leptin's promoter after TSA treatment revealed that histone H3 lysines 9 and 14 were acetylated.
We found that epigenetic mechanisms regulate leptin's expression in chondrocytes affecting its downstream target MMP-13. Small interference RNA against leptin deactivated directly MMP-13, which was upregulated after leptin's epigenetic reactivation, raising the issue of leptin's therapeutic potential for osteoarthritis.
研究表观遗传机制是否能够调节骨关节炎软骨细胞中瘦素的表达,并影响其下游靶点如金属蛋白酶3、9、13。
采用DNA亚硫酸氢盐测序法检测瘦素启动子区的DNA甲基化情况,通过实时定量PCR检测骨关节炎及正常软骨组织中mRNA的表达水平。骨关节炎关节软骨样本取自膝关节的两个不同部位(n = 15);一个来自最大负荷的主要缺损区域(晚期骨关节炎(OA)),另一个来自相邻的宏观上完整的区域(轻度OA)。使用小干扰RNA,我们检测了瘦素下调是否会影响基质金属蛋白酶(MMP)-13的活性。我们还评估了去甲基化剂5'-氮杂-2'-脱氧胞苷(AZA)和组蛋白脱乙酰酶抑制剂曲古抑菌素A(TSA)对软骨细胞培养物中瘦素表达的影响。此外,我们在瘦素启动子区域进行了染色质免疫沉淀。
我们发现瘦素表达与DNA甲基化之间存在相关性,并且瘦素可控制软骨细胞中MMP-13的活性。用小干扰RNA下调瘦素可显著抑制MMP-13的表达。在正常软骨细胞中应用5-AZA后,瘦素的甲基化水平降低,而其表达上调,且MMP-13被激活。此外,在正常软骨细胞培养物中应用TSA可增加瘦素的表达。同样,TSA处理后瘦素启动子区域的染色质免疫沉淀显示组蛋白H3赖氨酸9和14被乙酰化。
我们发现表观遗传机制可调节软骨细胞中瘦素的表达,影响其下游靶点MMP-13。针对瘦素的小干扰RNA可直接使MMP-13失活,而瘦素的表观遗传重新激活后MMP-13上调,这引发了瘦素对骨关节炎治疗潜力的问题。